Synopsis
Synopsis
0
EU WC
0
KDMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dextran
2. Dextran 40000
3. Dextran 70
4. Dextran 75
5. Dextran 80
6. Dextran B 1355
7. Dextran B 1355 S
8. Dextran B-1355
9. Dextran B-1355-s
10. Dextran B1355
11. Dextran B512
12. Dextran Derivatives
13. Dextran M 70
14. Dextran T 40
15. Dextran T 500
16. Dextran T 70
17. Dextran T-40
18. Dextran T-500
19. Dextrans
20. Hemodex
21. Hyskon
22. Infukoll
23. Macrodex
24. Polyglucin
25. Promit
26. Rheodextran
27. Rheoisodex
28. Rheomacrodex
29. Rheopolyglucin
30. Rondex
31. Saviosol
1. L3l3xyp7mp
2. Lmwd
3. Schembl206877
4. Chembl1697742
5. O-alpha-d-glucopyranosyl-(1.6)-o-alpha-d-glucopyranosyl-(1.6)-d-glucose
6. Hy-n0913a
7. Dtxsid701317190
8. 6-.alpha.-isomaltosylglucose
9. Zinc64622163
10. Cs-0109495
11. D-glucose, O-.alpha.-d-glucopyranosyl-(1->6)-o-.alpha.-d-glucopyranosyl-(1->6)-
12. O-alpha-d-glucopyranosyl-(1-->6)-o-alpha-d-glucopyranosyl-(1-->6)-d-glucose
13. Wurcs=2.0/2,3,2/[o2122h][a2122h-1a_1-5]/1-2-2/a6-b1_b6-c1
14. (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-((((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy)methyl)oxan-2-yl)oxy)hexanal
Molecular Weight | 504.4 g/mol |
---|---|
Molecular Formula | C18H32O16 |
XLogP3 | -7.2 |
Hydrogen Bond Donor Count | 11 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 11 |
Exact Mass | 504.16903493 g/mol |
Monoisotopic Mass | 504.16903493 g/mol |
Topological Polar Surface Area | 277 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 625 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 14 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Plasma Substitutes
Any liquid used to replace blood plasma, usually a saline solution, often with serum albumins, dextrans or other preparations. These substances do not enhance the oxygen- carrying capacity of blood, but merely replace the volume. They are also used to treat dehydration. (See all compounds classified as Plasma Substitutes.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19584
Submission : 2006-06-30
Status : Active
Type : II
Certificate Number : R1-CEP 1999-063 - Rev 03
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 999
Status : Valid
NDC Package Code : 49442-5001
Start Marketing Date : 2011-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23092
Submission : 2009-07-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1183
Submission : 1968-05-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1184
Submission : 1968-05-07
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 353
Submission : 1959-11-16
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 462
Submission : 1962-01-08
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2573
Submission : 1975-12-03
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9447
Submission : 1991-12-05
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Certificate Number : R1-CEP 1999-064 - Rev 03
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1000
Status : Valid
NDC Package Code : 49442-5001
Start Marketing Date : 2011-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING
Certificate Number : R1-CEP 1999-065 - Rev 03
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1001
Status : Valid
NDC Package Code : 49442-5001
Start Marketing Date : 2011-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1184
Submission : 1968-05-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1183
Submission : 1968-05-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19584
Submission : 2006-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23092
Submission : 2009-07-31
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 462
Submission : 1962-01-08
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 353
Submission : 1959-11-16
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9447
Submission : 1991-12-05
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2573
Submission : 1975-12-03
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Certificate Number : R1-CEP 2003-165 - Rev 01
Status : Valid
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1506
Certificate Number : R1-CEP 1999-065 - Rev 03
Status : Valid
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1001
Certificate Number : R1-CEP 1999-064 - Rev 03
Status : Valid
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 1000
Certificate Number : R1-CEP 1999-063 - Rev 03
Status : Valid
Issue Date : 2022-01-03
Type : Chemical
Substance Number : 999
Dextran sulfate sodium sulfur 5
Registration Number : 218MF10831
Registrant's Address : 2-41 Sasazukacho, Nishi-ku, Nagoya
Initial Date of Registration : 2006-10-20
Latest Date of Registration : 2006-10-20
Registration Number : 217MF11169
Registrant's Address : 2-41 Sasazukacho, Nishi-ku, Nagoya City, Aichi Prefecture
Initial Date of Registration : 2005-12-12
Latest Date of Registration : 2018-10-01
Dextran sulfate sodium sulfur-18
Registration Number : 218MF10826
Registrant's Address : 2-41 Sasazukacho, Nishi-ku, Nagoya
Initial Date of Registration : 2006-10-20
Latest Date of Registration : 2006-10-20
NDC Package Code : 49442-5070
Start Marketing Date : 2011-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 49442-5001
Start Marketing Date : 2011-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 49442-5800
Start Marketing Date : 2015-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49442-5600
Start Marketing Date : 2015-07-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49442-5040
Start Marketing Date : 2006-09-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49442-5060
Start Marketing Date : 2011-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100g/100g)
Marketing Category : DRUG FOR FURTHER PROCESSING
About the Company : PT. Cahaya Mandiri Farma is a leading company in the pharmaceutical industry, dedicated to producing high-quality healthcare products for humans. We are committed to excellence thr...
About the Company : SWATI SPENTOSE PVT. LTD.(SSPL), a pharmaceutical company based in Mumbai, India having 2 manufacturing sites: SSPL Unit 1 and SSPL Unit 2. Please find attached a brief presentation...
About the Company : Xi'an Wanlong Pharmaceutical Co., Ltd was founded in 1995 and it is comprehensive modern pharmaceutical enterprise which mainly produces formulations, API and intermediates, GMP & ...
About the Company : Xi'an Wanlong Pharmaceutical Co., Ltd was founded in 1995 and it is comprehensive modern pharmaceutical enterprise which mainly produces formulations, API and intermediates, GMP & ...
About the Company : Xi'an Wanlong Pharmaceutical Co., Ltd was founded in 1995 and it is comprehensive modern pharmaceutical enterprise which mainly produces formulations, API and intermediates, GMP & ...
Details:
OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.
Lead Product(s): HYDROXYPROPYLMETHYLCELLULOSE,Glycerine,Dextrans
Therapeutic Area: Ophthalmology Brand Name: Tears Naturale Forte
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: OcuMension Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 12, 2024
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Glycerine,Dextrans
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins
Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.
Product Name : Tears Naturale Forte
Product Type : Small molecule
Upfront Cash : Undisclosed
August 12, 2024
Details:
The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.
Lead Product(s): Dextrans
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: ILB
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Lead Product(s) : Dextrans
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tikomed's ILB® Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Ra...
Details : The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.
Product Name : ILB
Product Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2020
Regulatory Info :
Registration Country : Sweden
Brand Name : Macrodex 60 mg / ml with sodium
Dosage Form : SOLUTION FOR INFUSION
Dosage Strength : -
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Promit, Promiten
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 150 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Rheomacrodex 100 mg/ml med natriumklorid
Dosage Form : INFUSIONSVÄTSKA, LÖSNING
Dosage Strength : --
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Stranoval
Dosage Form :
Dosage Strength : Cream Derm 30 G 0.122% + 32,000 I.U./100 G_
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Macrodex with sodium chloride
Dosage Form : Infusion fluid, resolution
Dosage Strength : 60 mg/ml
Packaging : Plastic bag
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Plasmodex
Dosage Form : Infusion fluid, resolution
Dosage Strength : 30 g/1000 ml
Packaging : Plastic bag
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Promiten
Dosage Form : Injection fluid, resolution
Dosage Strength : 150 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Promiten
Dosage Form : Injection fluid, resolution
Dosage Strength : 150 mg/ml
Packaging : Ampoule of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Rescue flow
Dosage Form : Infusion fluid, resolution
Dosage Strength : 60 g/l/75 g/l
Packaging : Plastic bag
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Rescue flow
Dosage Form : Infusion fluid, resolution
Dosage Strength : 60 g/l/75 g/l
Packaging : Plastic bag
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
46
PharmaCompass offers a list of Dextrans API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dextrans manufacturer or Dextrans supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dextrans manufacturer or Dextrans supplier.
PharmaCompass also assists you with knowing the Dextrans API Price utilized in the formulation of products. Dextrans API Price is not always fixed or binding as the Dextrans Price is obtained through a variety of data sources. The Dextrans Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dextrans manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dextrans, including repackagers and relabelers. The FDA regulates Dextrans manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dextrans API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dextrans manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dextrans supplier is an individual or a company that provides Dextrans active pharmaceutical ingredient (API) or Dextrans finished formulations upon request. The Dextrans suppliers may include Dextrans API manufacturers, exporters, distributors and traders.
click here to find a list of Dextrans suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dextrans DMF (Drug Master File) is a document detailing the whole manufacturing process of Dextrans active pharmaceutical ingredient (API) in detail. Different forms of Dextrans DMFs exist exist since differing nations have different regulations, such as Dextrans USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dextrans DMF submitted to regulatory agencies in the US is known as a USDMF. Dextrans USDMF includes data on Dextrans's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dextrans USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dextrans suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dextrans Drug Master File in Japan (Dextrans JDMF) empowers Dextrans API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dextrans JDMF during the approval evaluation for pharmaceutical products. At the time of Dextrans JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dextrans suppliers with JDMF on PharmaCompass.
A Dextrans CEP of the European Pharmacopoeia monograph is often referred to as a Dextrans Certificate of Suitability (COS). The purpose of a Dextrans CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dextrans EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dextrans to their clients by showing that a Dextrans CEP has been issued for it. The manufacturer submits a Dextrans CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dextrans CEP holder for the record. Additionally, the data presented in the Dextrans CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dextrans DMF.
A Dextrans CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dextrans CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dextrans suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dextrans as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dextrans API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dextrans as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dextrans and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dextrans NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dextrans suppliers with NDC on PharmaCompass.
Dextrans Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dextrans GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dextrans GMP manufacturer or Dextrans GMP API supplier for your needs.
A Dextrans CoA (Certificate of Analysis) is a formal document that attests to Dextrans's compliance with Dextrans specifications and serves as a tool for batch-level quality control.
Dextrans CoA mostly includes findings from lab analyses of a specific batch. For each Dextrans CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dextrans may be tested according to a variety of international standards, such as European Pharmacopoeia (Dextrans EP), Dextrans JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dextrans USP).